TD Cowen analyst Charles Rhyee lowered the firm’s price target on Fortrea (FTRE) to $5 from $7 and keeps a Hold rating on the shares. The firm updated estimates to reflect continued soft biotech and large pharma.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FTRE: